QualityStocksNewsBreaks Archives - Page 800 of 1453

WednesdayFeb 10, 2021 12:23 pm

QualityStocksNewsBreaks – Sanwire Corp. (SNWR) Announces Creation and Launch of Label Incubator Program

Sanwire (OTC: SNWR), an innovative company with a focus on technologies for the entertainment industry, together with its wholly owned subsidiary Intercept Music Inc., today announced the formation and launch of its Label Incubator Program. The program works as a development suite of marketing and distribution services for artists who have been referred by interested record labels to enhance their online footprint and music exposure while further grooming and developing these artists to advance their path to a recording contract. "Our new Label Incubator Program may be one of the most impactful programs for both Intercept and the artistic clientele…

WednesdayFeb 10, 2021 11:51 am

QualityStocksNewsBreaks – Augusta Gold Inc. (CSE: G) (OTCQB: BFGCD) (FSE: 11B) Announces C$15M Fully Subscribed Private Placement

Augusta Gold (CSE: G) (OTCQB: BFGCD) (FSE: 11B) today announced a fully subscribed non-brokered private placement raising approximately C$15 million. Per the private placement, Augusta will offer 6.7 million units at a price of C$2.25 per unit with each unit comprised of one (1) common share of the company (a "common share") and one half (1/2) of one (1) common share purchase warrant (a "warrant"). Each full warrant entitles the holder to acquire one common share for a period of three years at an exercise price of C$2.80. Augusta Gold intends to utilize the proceeds to advance exploration efforts at…

WednesdayFeb 10, 2021 11:23 am

QualityStocksNewsBreaks – The Movie Studio Inc. (MVES) Releases Moviesode for ‘Cause & Effect’ Utilizing Groundbreaking Format

The Movie Studio (OTC: MVES) today announced the release of Moviesode 1 of the upcoming film “Cause & Effect” (https://vimeo.com/473177048/aaa0f80537 demonstrating the company’s disruptive business model. The company’s Moviesode process fractures linear production of motion picture manufacturing into chapters. When assimilated, the process utilizes the core movie trailer (https://vimeo.com/310897990) and completes the feature film while allowing talent integration, location and product placement to add to the value proposition during the film’s fabrication process. “We are excited to release the first Moviesode for ‘Cause & Effect’ utilizing our groundbreaking ideological format of abbreviated motion picture content manufacturing as we move forward…

WednesdayFeb 10, 2021 11:07 am

QualityStocksNewsBreaks – Harpoon Therapeutics Inc. (NASDAQ: HARP) Closes Underwritten $115M Follow-On Offering

Harpoon Therapeutics (NASDAQ: HARP), a clinical-stage immunotherapy company, announced that it has closed on a previously announced underwritten public offering. The offering consisted of 6,764,704 shares of HARP common stock, including 882,352 additional shares pursuant to the full exercise of the over-allotment option granted to the underwriters. The shares were purchased for $17 a share; the completed IPO resulted in an estimated $15 million in gross proceeds for Harpoon Therapeutics. Harpoon Therapeutics intends to use the proceeds, along with additional available funds, as it continues the clinical development of four products: HPN424 (“HPN424”) is targeting metastatic castration-resistant prostate cancer, HPN536…

WednesdayFeb 10, 2021 10:53 am

QualityStocksNewsBreaks – Friendable Inc.’s (FDBL) Fan Pass Appoints Industry Expert as New VP of Sales, Operations & Business Development

Friendable (OTC: FDBL), a mobile technology and marketing company focused on connecting and engaging users through its proprietary mobile and desktop applications, has named John Haugh as new VP. An industry expert with more than 25 years of experience, Haugh will manage operational growth, brand advertisers, sponsors and new revenue opportunities. Haugh, who himself is a music artist with more than 10,000 touring miles, offers a unique perspective to the new role. His vast background includes experience with media and advertising responsibilities, and he has worked with numerous publishing groups, websites, retail music operations and publishing groups. He has relationships…

WednesdayFeb 10, 2021 10:49 am

QualityStocksNewsBreaks – MAZAKALI CEO Authors Article on Healing Properties of Cannabis

MAZAKALI CEO Sumit Mehta authored a recent News Media online article titled “Cannabis = Indian Medicine, Is One of Humankind’s Most Ancient Healing Herbs.” MAZAKALI is a cannabis-focused fintech marketplace that offers full-scale digital capital raising and investment services across the cannabis complex, including hemp, real estate, supply chain, ancillary and international. In the article, Mehta explains that more than 100 medical applications of cannabis were recorded as far back as 2737 by the father of Chinese medicine, Emperor Shen Nung. Uses for the substance have continued to increase, with scientists in 1992 identifying a previously undiscovered regulation system within…

WednesdayFeb 10, 2021 10:23 am

QualityStocksNewsBreaks – TAAT(TM) Lifestyle & Wellness Ltd. (CSE: TAAT) (OTCQB: TOBAF) (FRANKFURT: 2TP2) Announces 233% Manufacturing Increase of Flagship Product

TAAT(TM) (CSE: TAAT) (OTCQB: TOBAF) (FRANKFURT: 2TP2) today announced that its flagship product TAAT(TM) is now being manufactured at a rate of more than 57,000 ten-pack cartons per month (over 690,000 cartons per year). According to the update, this represents a 233% increase from a production rate of 12 pallets per month to 40 pallets per month as of this week. The increase was prompted by sustained demand for TAAT(TM) in Ohio, as well as anticipated demand from smokers aged 21 and over in other U.S. states who will be able to purchase the product online directly from the company…

WednesdayFeb 10, 2021 10:14 am

QualityStocksNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Studying Potential for Psychedelics in Treatment of Mental Health Conditions, Announces Addition of Mescaline to Subsidiary Medicine Programs

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience accelerator at the leading-edge of the life science industry, is involved in preclinical laboratory work designed to study a variety of psychotropic compounds, including psilocybin, mescaline, LSD, MDMA and DMT. The company also announced that its subsidiary, XPhyto Laboratories Inc., has added the production of mescaline to its psychedelic medicine programs. These psychedelic compounds show promising potential in treating mental conditions because they are known to modulate neurotransmitters such as serotonin and dopamine, which regulate cognition, perception and mood in individuals. Called a leader in innovating psychedelic drugs in a recent…

WednesdayFeb 10, 2021 10:02 am

QualityStocksNewsBreaks – Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) Announces First Commercial Contract for CBD Oil

Pure Extracts Technologies (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ), a plant-based extraction company specializing in cannabis, hemp and mushroom products, has contracted for its initial commercial CBD oil sale. The company anticipated the contract will result in multiple shipments of its 85% pure CBD distillate offering this year. Pure Extracts’ state-of-the-art, subcritical/super-critical CO2 extraction system produces an exceptionally pure THC and CBD full-spectrum oil and distillate. The resulting distillate can be used to manufacture a variety of cannabis 2.0 products, such as beverages, edibles and vape pens. The announcement also noted that Pure Extracts continues its commitment to increase awareness.…

WednesdayFeb 10, 2021 9:31 am

QualityStocksNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Preparing Phase 3 Trial to Evaluate Neuroactive Nasal Spray Treatment for SAD

VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company developing new-generation medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (“CNS”) disorders, has announced plans to begin a Phase 3 clinical trial in Q2 2021. The clinical trial will evaluate PH94B (“PH94B”), a neuroactive nasal spray designed to provide rapid onset of action for the acute treatment of anxiety in adults with social anxiety disorder (“SAD”). With an estimated 20 million people in the United States suffering from SAD, it is one of the most prevalent mental health conditions in the…

Site Search

Company Search

Category: QualityStocksNewsBreaks